TriSalus Life Sciences Inc
Follow $TLSI
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TLSI by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TLSI moving today?
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TLSI overview
Related filings and maps
Congress activity in TLSI
No receipt-qualified Congressional disclosure is present for TLSI in the cached public ledger.
TLSI contract awards, year to date.
Public federal awards linked to this ticker.
TLSI lobbying filings, year to date.
Registered lobbying filings matched to TriSalus Life Sciences Inc.